CorMedix Inc. (CRMD)
NASDAQ: CRMD · Real-Time Price · USD
6.56
+0.10 (1.55%)
At close: Mar 9, 2026, 4:00 PM EDT
6.58
+0.02 (0.30%)
After-hours: Mar 9, 2026, 7:05 PM EDT

Company Description

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.

Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.

CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007.

The company was incorporated in 2006 and is based in Parsippany, New Jersey.

CorMedix Inc.
CorMedix logo
Country United States
Founded 2006
IPO Date Mar 25, 2010
Industry Biotechnology
Sector Healthcare
Employees 65
CEO Joseph Todisco

Contact Details

Address:
389 Interpace Pkwy, Suite 450
Parsippany, New Jersey 07054
United States
Phone 908 517 9500
Website cormedix.com

Stock Details

Ticker Symbol CRMD
Exchange NASDAQ
Stock Type Common Stock
Share Class Class A Shares
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001410098
CUSIP Number 21900C308
ISIN Number US21900C3088
SIC Code 2834

Key Executives

Name Position
Joseph Todisco MBA Chief Executive Officer and Chairman of the Board of Directors
Elizabeth Masson-Hurlburt B.A. Executive Vice President, Chief Operating Officer and Chief Integration Officer
Dr. Matthew T. David M.D. Executive Vice President and Chief Business Officer
Susan Blum Executive Vice President and Chief Financial Officer
Kaufman Beth Zelnick Esq. EVice President, Chief Legal and Compliance Officer and Corporate Secretary
Beth Steinbrenner SVice President and Chief Human Resource Officer
Donna Ucci Senior Vice President and Head of Global Quality
Dr. Tushar Mukherjee Senior Vice President and Head of Technical Operations
Michael Seckler Executive Vice President and Chief Commercial Officer
Dr. Peter Sullivan BCOP, Pharm.D. Senior Vice President of Market Access

Latest SEC Filings

Date Type Title
Mar 6, 2026 8-K Current Report
Mar 5, 2026 10-K Annual Report
Mar 5, 2026 8-K Current Report
Jan 21, 2026 144 Filing
Jan 8, 2026 8-K Current Report
Jan 2, 2026 SCHEDULE 13G/A Filing
Dec 30, 2025 144 Filing
Dec 18, 2025 144 Filing
Dec 9, 2025 144 Filing
Dec 9, 2025 144 Filing